A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin independence.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

I sat through almost every day of Letby's two trials at Manchester Crown Court - and subsequent appeals - and admit I was ...

Although gut microbiota and lipid metabolites have been suggested to be closely associated with type 2 diabetes mellitus (T2DM), the interactions between gut microbiota, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Techniques such as site-directed ... of insulin by delaying entry of individual insulin molecules into the bloodstream from the site of injection (usually subcutaneous or intramuscular).

The Global Stem Cell Therapy For Diabetes Related Conditions market industry is primarily driven by the continuous advancements in technology.

The chef and television presenter on his love of football, the importance of staying positive, and his compulsion to keep the ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

Julie Clennell, Director of Nursing, Allied Health Professionals and Quality – Locala Community Partnerships. Background to learning Locala is a Social Enterprise, community provider of NHS funded ...

We recently developed a novel GLP-1 mimetics (supaglutide) by genetically engineering recombinant fusion protein production techniques ... a week injection of supaglutide exerted body weight-sparing ...